Ryvu Therapeutics S.A.

WSE:RVU Stock Report

Market Cap: zł894.7m

Ryvu Therapeutics Valuation

Is RVU undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of RVU when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate RVU's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate RVU's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for RVU?

Key metric: As RVU is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for RVU. This is calculated by dividing RVU's market cap by their current revenue.
What is RVU's PS Ratio?
PS Ratio9.5x
Saleszł91.18m
Market Capzł894.75m

Price to Sales Ratio vs Peers

How does RVU's PS Ratio compare to its peers?

The above table shows the PS ratio for RVU vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average10x
SLV Selvita
2.6x17.5%zł871.9m
MDB Medicofarma Biotech
25.7xn/azł27.5m
CLN Celon Pharma
6.7x6.8%zł1.4b
SVE Synthaverse
4.9xn/azł304.6m
RVU Ryvu Therapeutics
9.5x19.3%zł867.0m

Price-To-Sales vs Peers: RVU is good value based on its Price-To-Sales Ratio (9.5x) compared to the peer average (10x).

Price to Sales Ratio vs Industry

How does RVU's PS Ratio compare vs other companies in the European Life Sciences Industry?

5 CompaniesPrice / SalesEstimated GrowthMarket Cap
RVU 9.5xIndustry Avg. 4.7xNo. of Companies7PS03.26.49.612.816+
5 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: RVU is expensive based on its Price-To-Sales Ratio (9.5x) compared to the European Life Sciences industry average (4.7x).

Price to Sales Ratio vs Fair Ratio

What is RVU's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

RVU PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio9.5x
Fair PS Ratio8.9x

Price-To-Sales vs Fair Ratio: RVU is expensive based on its Price-To-Sales Ratio (9.5x) compared to the estimated Fair Price-To-Sales Ratio (8.9x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst RVU forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Currentzł37.50
zł65.83
+75.5%
22.8%zł80.00zł40.80n/a4
Jan ’26zł38.50
zł65.83
+71.0%
22.8%zł80.00zł40.80n/a4
Dec ’25zł45.00
zł82.65
+83.7%
18.4%zł108.10zł68.50n/a4
Nov ’25zł44.80
zł78.70
+75.7%
16.4%zł99.30zł67.00n/a4
Oct ’25zł52.40
zł78.70
+50.2%
16.4%zł99.30zł67.00n/a4
Sep ’25zł53.70
zł77.95
+45.2%
17.5%zł99.30zł64.00n/a4
Aug ’25zł53.60
zł77.95
+45.4%
17.5%zł99.30zł64.00n/a4
Jul ’25zł49.00
zł77.95
+59.1%
17.5%zł99.30zł64.00n/a4
Jun ’25zł54.00
zł70.83
+31.2%
9.5%zł80.00zł64.00n/a3
May ’25zł49.50
zł73.13
+47.7%
9.7%zł80.00zł64.00n/a4
Apr ’25zł55.20
zł71.88
+30.2%
8.5%zł80.00zł64.00n/a4
Mar ’25zł59.00
zł73.13
+23.9%
9.7%zł80.00zł64.00n/a4
Feb ’25zł56.00
zł71.43
+27.5%
12.1%zł80.00zł61.70n/a4
Jan ’25zł57.50
zł71.43
+24.2%
12.1%zł80.00zł61.70zł38.504
Dec ’24zł59.70
zł71.43
+19.6%
12.1%zł80.00zł61.70zł45.004
Nov ’24zł60.50
zł70.43
+16.4%
10.5%zł80.00zł61.70zł44.804
Oct ’24zł65.20
zł72.57
+11.3%
11.1%zł81.00zł61.70zł52.403
Sep ’24zł60.90
zł72.57
+19.2%
11.1%zł81.00zł61.70zł53.703
Aug ’24zł58.30
zł72.57
+24.5%
11.1%zł81.00zł61.70zł53.603
Jul ’24zł60.40
zł72.23
+19.6%
10.7%zł80.00zł61.70zł49.003
Jun ’24zł56.00
zł72.23
+29.0%
10.7%zł80.00zł61.70zł54.003
May ’24zł56.00
zł72.23
+29.0%
10.7%zł80.00zł61.70zł49.503
Apr ’24zł59.20
zł72.23
+22.0%
10.7%zł80.00zł61.70zł55.203
Mar ’24zł63.70
zł62.90
-1.3%
21.5%zł80.00zł47.00zł59.003
Feb ’24zł53.40
zł55.70
+4.3%
15.6%zł64.40zł47.00zł56.002
Jan ’24zł49.25
zł55.70
+13.1%
15.6%zł64.40zł47.00zł57.502
Analyst Price Target
Consensus Narrative from 4 Analysts
zł65.83
Fair Value
43.0% undervalued intrinsic discount
4
Number of Analysts

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/09 19:09
End of Day Share Price 2025/01/09 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Ryvu Therapeutics S.A. is covered by 9 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Kamil KliszczBiuro maklerskie mBanku
Beata Szparaga-WasniewskaBiuro maklerskie mBanku
Jonas PeciulisEdison Investment Research